OncoCyte Corp
OCX
Company Profile
Business description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Contact
15 Cushing
IrvineCA92618
USAT: +1 949 409-7600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2024
Employees
46
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,471.50 | 18.80 | 0.22% |
| CAC 40 | 7,282.69 | 10.37 | 0.14% |
| DAX 40 | 19,848.77 | 35.98 | -0.18% |
| Dow JONES (US) | 43,209.68 | 87.35 | -0.20% |
| FTSE 100 | 8,136.99 | 34.27 | 0.42% |
| HKSE | 20,098.29 | 215.16 | 1.08% |
| NASDAQ | 19,939.66 | 91.46 | -0.46% |
| Nikkei 225 | 39,568.06 | 437.63 | 1.12% |
| NZX 50 Index | 13,074.74 | 86.71 | 0.67% |
| S&P 500 | 6,021.83 | 18.21 | -0.30% |
| S&P/ASX 200 | 8,220.90 | 19.30 | 0.24% |
| SSE Composite Index | 3,393.53 | 42.27 | 1.26% |